The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020
Margherita Pizzato
1, 2
,
Mengmeng Li
3
,
Jérôme Vignat
2
,
Mathieu Laversanne
1
,
Deependra Vikram Singh
1
,
C La Vecchia
1
,
Salvatore Vaccarella
2
Publication type: Journal Article
Publication date: 2022-04-01
scimago Q1
wos Q1
SJR: 12.190
CiteScore: 64.2
Impact factor: 41.8
ISSN: 22138587, 22138595
PubMed ID:
35271818
Endocrinology
Endocrinology, Diabetes and Metabolism
Internal Medicine
Abstract
Thyroid cancer incidence rates have increased in many countries and settings; however, mortality rates have remained stable at lower rates. This epidemiological pattern has been largely attributed to an overdiagnosis effect. Timely evidence for the global epidemiological status is necessary to identify the magnitude of this problem and the areas mostly affected by it. We therefore aimed to provide an up-to-date assessment on the global distribution of thyroid cancer incidence and mortality rates in 2020.We extracted age-standardised incidence and mortality rates per 100 000 person-years of thyroid cancer as defined by the International Classification of Diseases for Oncology 10th Revision (code C73), for 185 countries or territories by sex and 18 age groups (ie, 0-4, 5-9, …, 80-84, and ≥85 years) from the GLOBOCAN database. Both incidence and mortality estimates were presented by country and aggregated across the 20 UN-defined world regions and according to the UN's four-tier Human Development Index (ie, low, medium, high, and very high) in 2020.Globally, in 2020, the age-standardised incidence rates of thyroid cancer were 10·1 per 100 000 women and 3·1 per 100 000 men, and age-standardised mortality rates were 0·5 per 100 000 women and 0·3 per 100 000 men. In both sexes, incidence rates were five times higher in high and very high Human Development Index countries than in low and medium Human Development Index countries, whereas mortality rates were relatively similar across different settings. Incidence rates in women differed by more than 15 times across world regions, with the highest incidence rates being in the Federated States of Micronesia and French Polynesia (18·5 per 100 000 women), North America (18·4 per 100 000), and east Asia (17·8 per 100 000, with South Korea reaching 45 per 100 000). Mortality rates were less than one per 100 000 in most countries and in both sexes. South Korea had the highest incidence-to-mortality rate ratio in both sexes, followed by Cyprus and Canada.The current thyroid cancer epidemiological landscape is strongly suggestive of a large effect of overdiagnosis in many countries and settings worldwide, confirming the relevance of thyroid cancer overdiagnosis as a global public health problem.None.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
5
10
15
20
25
30
35
|
|
|
Frontiers in Endocrinology
33 publications, 6.82%
|
|
|
Frontiers in Oncology
21 publications, 4.34%
|
|
|
Endocrine
21 publications, 4.34%
|
|
|
Cancers
20 publications, 4.13%
|
|
|
Scientific Reports
12 publications, 2.48%
|
|
|
Thyroid
11 publications, 2.27%
|
|
|
Medicine (United States)
8 publications, 1.65%
|
|
|
Journal of Clinical Endocrinology and Metabolism
6 publications, 1.24%
|
|
|
Cureus
6 publications, 1.24%
|
|
|
Gland Surgery
6 publications, 1.24%
|
|
|
Heliyon
5 publications, 1.03%
|
|
|
Frontiers in Microbiology
4 publications, 0.83%
|
|
|
Frontiers in Nutrition
4 publications, 0.83%
|
|
|
Biomedicines
4 publications, 0.83%
|
|
|
The Lancet Diabetes and Endocrinology
4 publications, 0.83%
|
|
|
International Journal of Molecular Sciences
4 publications, 0.83%
|
|
|
BMC Cancer
4 publications, 0.83%
|
|
|
European Thyroid Journal
4 publications, 0.83%
|
|
|
Oncology Letters
4 publications, 0.83%
|
|
|
Healthcare
3 publications, 0.62%
|
|
|
Journal of Cancer Research and Clinical Oncology
3 publications, 0.62%
|
|
|
International Journal of Hyperthermia
3 publications, 0.62%
|
|
|
International Journal of General Medicine
3 publications, 0.62%
|
|
|
Frontiers in Immunology
3 publications, 0.62%
|
|
|
International Journal of Endocrinology
3 publications, 0.62%
|
|
|
Nature Reviews Endocrinology
3 publications, 0.62%
|
|
|
Thyroid Research
3 publications, 0.62%
|
|
|
World Journal of Surgical Oncology
3 publications, 0.62%
|
|
|
Journal of Clinical Medicine
3 publications, 0.62%
|
|
|
5
10
15
20
25
30
35
|
Publishers
|
20
40
60
80
100
120
140
|
|
|
Springer Nature
122 publications, 25.21%
|
|
|
Frontiers Media S.A.
76 publications, 15.7%
|
|
|
Elsevier
65 publications, 13.43%
|
|
|
MDPI
52 publications, 10.74%
|
|
|
Wiley
31 publications, 6.4%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
17 publications, 3.51%
|
|
|
Mary Ann Liebert
12 publications, 2.48%
|
|
|
Taylor & Francis
12 publications, 2.48%
|
|
|
The Endocrine Society
8 publications, 1.65%
|
|
|
AME Publishing Company
7 publications, 1.45%
|
|
|
SAGE
7 publications, 1.45%
|
|
|
Bioscientifica
7 publications, 1.45%
|
|
|
Spandidos Publications
6 publications, 1.24%
|
|
|
Baishideng Publishing Group
4 publications, 0.83%
|
|
|
Oxford University Press
4 publications, 0.83%
|
|
|
American Chemical Society (ACS)
4 publications, 0.83%
|
|
|
Hindawi Limited
3 publications, 0.62%
|
|
|
Cold Spring Harbor Laboratory
3 publications, 0.62%
|
|
|
Research Square Platform LLC
3 publications, 0.62%
|
|
|
American Diabetes Association
2 publications, 0.41%
|
|
|
Georg Thieme Verlag KG
2 publications, 0.41%
|
|
|
Public Library of Science (PLoS)
2 publications, 0.41%
|
|
|
Institute of Electrical and Electronics Engineers (IEEE)
2 publications, 0.41%
|
|
|
PeerJ
2 publications, 0.41%
|
|
|
Endocrinology Research Centre
2 publications, 0.41%
|
|
|
Apex Publishing
2 publications, 0.41%
|
|
|
American Medical Association (AMA)
1 publication, 0.21%
|
|
|
Society of Nuclear Medicine
1 publication, 0.21%
|
|
|
Korean Endocrine Society
1 publication, 0.21%
|
|
|
20
40
60
80
100
120
140
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
485
Total citations:
485
Citations from 2024:
354
(73.14%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Pizzato M. et al. The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020 // The Lancet Diabetes and Endocrinology. 2022. Vol. 10. No. 4. pp. 264-272.
GOST all authors (up to 50)
Copy
Pizzato M., Li M., Vignat J., Laversanne M., Singh D. V., La Vecchia C., Vaccarella S. The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020 // The Lancet Diabetes and Endocrinology. 2022. Vol. 10. No. 4. pp. 264-272.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1016/S2213-8587(22)00035-3
UR - https://doi.org/10.1016/S2213-8587(22)00035-3
TI - The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020
T2 - The Lancet Diabetes and Endocrinology
AU - Pizzato, Margherita
AU - Li, Mengmeng
AU - Vignat, Jérôme
AU - Laversanne, Mathieu
AU - Singh, Deependra Vikram
AU - La Vecchia, C
AU - Vaccarella, Salvatore
PY - 2022
DA - 2022/04/01
PB - Elsevier
SP - 264-272
IS - 4
VL - 10
PMID - 35271818
SN - 2213-8587
SN - 2213-8595
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2022_Pizzato,
author = {Margherita Pizzato and Mengmeng Li and Jérôme Vignat and Mathieu Laversanne and Deependra Vikram Singh and C La Vecchia and Salvatore Vaccarella},
title = {The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020},
journal = {The Lancet Diabetes and Endocrinology},
year = {2022},
volume = {10},
publisher = {Elsevier},
month = {apr},
url = {https://doi.org/10.1016/S2213-8587(22)00035-3},
number = {4},
pages = {264--272},
doi = {10.1016/S2213-8587(22)00035-3}
}
Cite this
MLA
Copy
Pizzato, Margherita, et al. “The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020.” The Lancet Diabetes and Endocrinology, vol. 10, no. 4, Apr. 2022, pp. 264-272. https://doi.org/10.1016/S2213-8587(22)00035-3.